Blackstone-backed AGS Health has updated its IPO filing with SEBI, aiming to raise Rs 4,800 crore. The plan includes a fresh issue of Rs 1,800 crore, with a significant portion allocated to debt repayment. This offering marks a key move for the US-focused healthcare revenue management company as it prepares for public listing.
Blackstone-backed AGS Health has moved forward with its public listing plans, submitting an updated draft red herring prospectus (DRHP) to the Securities and Exchange Board of India (SEBI). The company is looking to raise a total of Rs 4,800 crore through this initial public offering (IPO), which received regulatory approval earlier this year in June 2026.
The proposed IPO structure consists of a fresh issue of shares worth Rs 1,800 crore and an offer-for-sale (OFS) component of Rs 3,000 crore. In an offer-for-sale, existing shareholders sell their shares to the public, meaning the proceeds from that specific portion do not go to the company’s treasury but rather to the selling investor. In this case, the selling entity is BCP Asia II Topco VIII Pte, an investment arm of The Blackstone Group.
A central focus of this IPO is debt reduction. The company plans to use approximately Rs 1,600 crore from the fresh issue proceeds to pay off outstanding borrowings held by its indirect subsidiaries, AGS Health BCP LLC and AGS Health BCP Holdings, Inc. For prospective investors, understanding the company's debt position is important, as its consolidated borrowings stood at Rs 4,238.8 crore as of March 2026. Reducing this debt load is a key objective for the company’s capital allocation strategy.
AGS Health operates in the US healthcare sector, providing revenue cycle management services. Essentially, the company helps US hospitals and physician groups manage patient billing, medical coding, and collection processes. As of March 2026, the company served 82 health systems, including some of the largest hospital networks in the United States. For the fiscal year ending March 2026, the firm reported consolidated revenue of Rs 2,041.4 crore and a profit of Rs 206.9 crore.
Investors monitoring the IPO should consider the company’s specific business model and associated risks. Because the firm earns its revenue primarily from the US healthcare market, it is exposed to changes in US healthcare regulations, insurance reimbursement policies, and potential fluctuations in foreign currency exchange rates. Additionally, the company faces the challenge of scaling its technology-led services while maintaining operational efficiency across its client base.
While the company has received approval to proceed, the final timing of the issue will depend on market conditions. Potential investors may want to watch for updates regarding the final price band, the specific dates for the subscription period, and any further management commentary on how the debt repayment will impact the company's interest costs and future cash flow.